These results indicated that BCL10 inhibition can result in differential cell cycle arrest in the two different pancreatic cancer cell lines: mutant KRAS cell lines (G2/M arrest) and wild-type KRAS cell lines (G1 arrest). Here, BCL10 is linked to familial pancreatic carcinoma.